Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
31.51
-1.83 (-5.49%)
Sep 3, 2025, 3:39 PM - Market open
Zai Lab Revenue
Zai Lab had revenue of $109.98M in the quarter ending June 30, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $427.80M, up 32.56% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$427.80M
Revenue Growth
+32.56%
P/S Ratio
8.15
Revenue / Employee
$228,892
Employees
1,869
Market Cap
3.51B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ZLAB News
- 1 day ago - Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong - Business Wire
- 6 days ago - Zai Lab Announces Participation in Investor Conferences in September 2025 - Business Wire
- 15 days ago - Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer - Business Wire
- 21 days ago - Zai Lab Establishes Oncology Scientific Advisory Board - Business Wire
- 26 days ago - Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 7 weeks ago - Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025 - Business Wire
- 2 months ago - Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer - Business Wire